Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bizaxofusp - Medicenna Therapeutics

X
Drug Profile

Bizaxofusp - Medicenna Therapeutics

Alternative Names: cpIL4-PE; Empowered Superkine targeting the IL-4R - Medicenna Therapeutics; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA); Neurocrine Biosciences
  • Developer Medicenna Therapeutics; Neurocrine Biosciences; Sophiris Bio
  • Class Antineoplastics; Immunotoxins; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma
  • No development reported Bladder cancer; Brain cancer; Diffuse intrinsic pontine glioma
  • Discontinued Solid tumours

Most Recent Events

  • 03 Jun 2024 Updated efficacy data from a phase IIb trial in Glioblastoma released by Medicenna Therapeutics
  • 31 May 2024 Updated efficacy data from a phase II trial in Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 14 Feb 2024 Bizaxofusp plans to seek Breakthrough therapy designation from the US FDA for Glioblastoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top